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Abstract 
Type 2 diabetes mellitus is an insidious disease that is increasingly present in 
geriatric population [1]. The greatest difficulty is represented by glycaemic 
control in geriatric patients often not very compliant with diet therapy and 
drug therapy. A new insulin glargine 300 units/ml formulation seems im-
prove patient compliance due to the lower volume of insulin to be injected 
and improved glycaemic control over 24 hours. The HRV signal, derived 
from digital electrocardiographic recording, is the simplest and most imme-
diate analysis that consists in calculating some temporal parameters [2]. HRV 
is a simple statistics derived from beat-beat intervals of sinus origin expressed 
as units of time in milliseconds. Data in the literature indicate that a decrease 
in HRV, measured with time domain analysis, denotes a worse prognosis 
and/or an increased risk of mortality in patients with heart disease, especially 
in the elderly ones.  
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1. Background 
Type 2 diabetes mellitus is increasingly present geriatric population [1]. Re-
cently, a new 300 units/ml insulin glargine formulation has been introduced in 
clinical practice to improve patient compliance due to lower volume of insulin to 
be injected and improved glycemic control within 24 hours. The HRV signal, 
derived from digital electrocardiographic recording, allows us to calculate some 
temporal parameters [2]. Data in the literature indicate that a decrease in HRV, 
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measured by the analysis of the time domain, shows a worse prognosis in par-
ticular in the elderly. 
2. Aim 
The aim of our study is to evaluate, through the Heart Rate Variability study, the 
possible influence of the new insulin glargine formulation 300 units/ml [3] on 
the neurovegetative tone and on the arrhythmic cardiovascular risk. 
3. Materials and Methods 
In the period between February 2018 and April 2018 we enrolled 30 patients. 5 
patients (16.6%) are not compliant and therefore the real number of enrolled pa-
tients is 25 (13 male and 12 female) with an average age of 75 ± 13 years with 
type II diabetes mellitus. All patients gave their informed consent and ethical 
approval. In the enrolment phase, the patients underwent the evaluation of the 
glycaemic profile at 20.00 by means of glucostick and the subsequent digital 
electrocardiographic recording by means of a Medixai electrocardiograph. Elegi-
bility patient have diabetes mellitus treated with insulin glargine. Exclusion cri-
teria are the presence of atrial fibrillation for BIAS in HRV evaluation. At the 
end of the enrolment, the patients were treated with the new insulin glargine 
formulation 300 units/ml at the same dosage as the old insulin glargine. After 1 
hour from insulin administration, the patients were again subjected to the 
evaluation of the glycaemic profile by means of glucostick and to the subsequent 
recording of digital control electrocardiography. The pre and post-treatment gly-
caemic values were used as a parameter to confirm the action of insulin glargine, 
administered to patients. 
The analysis of the HRV in the time domain was performed using the Kubios 
software for Windows XP. For this study were used statistical parameters of STD 
variability or standard deviation of the R-R intervals with respect to the mean; 
NN50 or number of consecutive intervals with difference > 50 msec; pNN50 or 
percentage of the NN50 intervals compared to the total of the measured intervals 
(a threshold of 20 msec can demonstrate superior discrimination between physio-
logical and pathological HRV) [4]; RMSSD or square root of the mean squared 
differences between adjacent R-R intervals; SDNN or calculation of the standard 
deviation of a series of intervals NN, AR LF/HF or regression analysis of the 
LF/HF ratio. Statistical analysis was performed with Paired T-test for small group 
of the patients using the Sigmastat 3.5 software for windows XP. 
4. Results 
The results of our study have shown that the new formulation of insulin glargine 
(300 units/ml) [5], even though it has determined a statistically significant re-
duction in glycaemic values due to insulin glargine activity (Table 1) before the 
electrocardiographic recording performed as a control, and a statistically signif-
icant increase of the Heart Rate index of a reduction in heart rate frequencies  
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Table 1. Descriptive statistics: RRvar STD (standard deviation of the R-R intervals com-
pared to the mean); NN50 (number of consecutive intervals with difference > 50 msec); 
pNN50 (percentage of the NN50 intervals with respect to the total of the measured inter-
vals, with a threshold of 20 msec); RMSSD (square root of the average of the squared dif-
ferences between adjacent R-R intervals); SDNN (calculation of the standard deviation of 
a series of intervals NN); AR LF/HF (regression analysis of the LF/HF ratio). “*”: statisti-
cally significant changes. 
 Base ± DS Control ± DS Probability (P) 
Glucose (mg/dl) 242.500 ± 77.768 190.500 ± 72.109 P < 0.001* 
RR var (ms) 811.717 ± 176.049 839.942 ± 177.081 P = 0.035* 
NN50 (ms) 58.542 ± 66.835 61.833 ± 69.133 P = 0.691 
pNN50 23.242 ± 26.540 23.600 ± 26.317 P = 0.892 
RMSSD 53.600 ± 46.600 57.508 ± 54.778 P = 0.577 
SDNN 43.271 ± 36.614 43.500 ± 41.433 P = 0.961 
AR LF/HF 1.457 ± 1.965 1.390 ± 2.208 P = 0.910 
 
(Table 1), but does not establish any statistically significant changes in neurove-
getative tone, that would negatively affect the cardiovascular risk in geriatric pa-
tients with multiple co-morbidities. 
5. Discussion 
Insulin glargine is a human insulin analog designed to have a low pH neutral 
solubility while the solubility is highest for pH values equal to 4. After subcuta-
neous injection, the acidic insulin solution is neutralized giving rise to the for-
mation of precipitate insulin which gradually releases small amounts of insulin 
glargine. 
The administration of the new insulin glargine formulation (300 units/ml) al-
lows improving the glycaemic profile in 24 hours as reported by the pharmaco-
dynamic studies that have shown how the insulin effect persists up to 36 hours, 
due to the prolonged release of insulin glargine from the precipitate of this new 
formulation. This can be attributable to the reduction in injection volume of 
about 2/3. Such reduction in injection volume leads to a decrease in the area of 
the precipitate responsible for the release of soluble glargine insulin. The dosage 
of the new insulin glargine can be optimized by adding 10% - 20% of the usual 
dosage of the old-generation insulin glargine (100 units/ml) since the insulin 
glargine of the old generation (100 units/ml) and the new formulation of insulin 
glargine (300 units/ml) are not bioequivalent and are not directly interchangea-
ble. 
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According to the data sheet, the dosage of the new generation glargine insulin 
(300 units/ml) can be calculated with the formula 0.2 units/kg of body weight or 
increasing the dosage of the new generation insulin by 10% - 20% (300 units/ml) 
compared to the old glargine insulin dosage (100 units/ml). The new insulin 
glargine formulation ensure a good control of glycaemia [6] and ensure a neu-
trality in terms of effects on arrhythmic cardiovascular risk, which represent a 
highly represented problem in the geriatric population affected by co-morbidities 
such as heart failure, atrial fibrillation and electrolyte disorders, concomitant 
with chronic renal function abnormalities. 
6. Conclusion 
Preliminary data obtained from our study shown that the new insulin glargine 
formulation 300 units/ml represents a new therapeutic option that allows im-
proving the glycaemic profile (Figure 1), given the best solubility in relation to 
the minor surface of the precipitate [6] and improve with a statistically signifi-
cant variation the RR-variability (confirmed by the data deriving from the analy-
sis of the RR variability index) (Figure 2) without altering the neurovegetative 
structure and therefore the cardiovascular risk (confirmed by the data deriving 
from the regression analysis of the LF/HF ratio). Our data give comfortable re-
sults but further evaluations are needed to have conclusive results. 
 
 
Figure 1. Descriptive statistics about glucose value. “*”: statistically significant changes. 
 
 
Figure 2. Descriptive statistics about R-R variability index. “*”: statistically significant 
changes. 
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